|Former: Atención Farmacéutica|
|Journal edited by Rasgo Editorial since 1983|
Manuela Velázquez Prieto
EDITOR IN CHIEF
Jaime E. Poquet Jornet
Tomás Casasín Edo
Virginia Hernández Corredoira
Ramón Jódar Masanés
Juan Carlos Juárez Giménez
Volume 19 - Issue 3, May-June 2017
ANALYSIS OF THE PEDIATRIC POPULATION OF CYSTIC FIBROSIS FOR THE IMPROVEMENT OF PHARMACEUTICAL CARE
DEL RÍO VALENCIA JUAN CARLOS, TAMAYO BERMEJO ROCÍO, GALLEGO FERNÁNDEZ CARMEN
Introduction. Patients with cystic fibrosis are chronic patients so due to their prevalence,the study of their characteristics deserves special dedication to respond to their needs. The intervention of the pharmacist in the care of patients responds to the need to optimize a pharmacological treatment which is complex and it is administered through different ways and with a high risk of causing adverse effects and interactions.
The hospital pharmacist has identified the chronic patient as the core of the new care model and he is working on models that allow us to define, homogenize and stratify in order to prioritize pharmaceutical care to these patients. The aim is to analyze the pediatric population of cystic fibrosis treated to optimize the pharmaceutical
Method. Cross-sectional study in which pediatric patients affected by fibrosis are analyzed. The Model of Selection and Pharmaceutical Care for Pediatric Chronic Patients of the Spanish Society of Hospital Pharmacy (SEFH) is used for the development of the study.
Results. We analyzed 33 pediatric patients affected by cystic fibrosis between the ages of 4 months and 16 years, with 63.63% being men. Patients are stratified into four levels: 9 patients (27.3%) belong to risk level 1, 14 (42.4%) to level 2, 9 (27.3%) to level 3 and 1 patient (3%) to level 4. Also notable is that 32 patients (96.9%) suffer multi-pathological processes, 31 patients (93.9%) are polymedicated, 100% have
complex administration patterns and 100% use high-risk medicines.
Conclusions. Knowing the characteristics and needs of a population will allow the development of interventions that may contribute to improve pharmacotherapy and the use of chronic pediatric patient’s medicines.
CYSTIC FIBROSIS – PEDIATRIC CHRONIC PATIENTS – STRATIFICATION